A comparison of the efficacy of long-term therapy with Rivaroxaban and short-term therapy with Enoxaparin for preventing venous thromboembolism after hip joint arthroplasty. Results of studies. RECORD 2
Keywords:hip joint arthroplasty, venous thromboembolism, anticoagulants
The article contains results of multinational multicentre trials RECORD for studying the clinical application of Xarelto® (Rivaroxaban) for prevention of thrombosis. The author shows that a long-term taking of Xarelto® considerably decreases the rate of development of venous thromboembolism, including symptomatic thromboses, in patients after total hip joint arthroplasty versus short-term prophylaxis with Enoxaparin plus placebo.
Prevention of fatal postoperative pulmonary embolism by low doses of heparin. An international multicentre trial [Text] / V. V. Kakkar, T. P. Corrigan, D. P. Fossard et al. // Lancet. — 1975. — V. 306. — P. 45–51.
NIH. Prevention of venous thrombosis and pulmonary embolism [Text] // NIH consensus statement. — 1986. — V. 6. — P. 1–8.
Making health care safer: a critical analysis of patient safety practices [Електронний ресурс] / K. G. Shojania, B. W. Duncan, K. M. McDonald, R. M. Wachter. — Режим доступу: http://www.ahrq.gov/clinic/ptsafety/pdf/ptsafety.pdf (accessed May 23, 2008).
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy [Text] / W. H. Geerts, G. F. Pineo, J. A. Heit et al. // Chest. — 2004. — V. 126. — P. 338–400.
Scottish Intercollegiate Guidelines Network (SIGN). Prophylaxis of venous thromboembolism [Text] / A national clinical guideline. — Edinburgh: SIGN Publication, 2002.
NICE. Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in inpatients undergoing surgery [Електронний ресурс]: NICE clinical guidelines. — Режим доступу: www.nice.org.uk/nicemedia/pdf/VTEFullGuide.pdf (accessed May 23, 2008).
Eikelboom J. W. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials [Text]/ J. W. Eikelboom, D. J. Quinlan, J. D. Douketis // Lancet. — 2001. — V. 358. — P. 9–15.
Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review [Text] / R. D. Hull, G. F. Pineo, P. D. Stein et al. // Ann Inter.
Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry [Text] / D. Warwick, R. J. Friedman, G. Agnelli et al. // J Bone Joint Surg Br. — 2007. — V. 89. — P. 799–807.
Pulmonary Embolism Prevention (PEP) trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial [Text] // Lancet. — 2000. — V. 355. — P. 1295–302.
American Academy of Orthopaedic Surgeons clinical guideline on prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty [Електронний ресурс]. — Режим доступу: www.aaos.org/Research/guidelines/PE_guideline.pdf (accessed May 23, 2008).
Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996–2001: findings from the Hip and Knee Registry [Text] / F. A. Anderson Jr., J. Hirsh, K. White, R. H. Fitzgerald Jr. // Chest. — 2003. — V. 124. — P. 349–356.
Prophylaxis for thromboembolic disease: recommendations from the American College of Chest Physicians — are they appropriate for orthopaedic surgery? [Text] / J. J. Callaghan, L. D. Dorr, G. A. Engh et al. // J. Arthroplasty. — 2005. — V. 20. — P. 273–274.
Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty [Text] / R. H. White, P. S. Romano, H. Zhou, J. Rodrigo, W. Bargar // Arch Intern Med. — 1998. — V. 158. — P. 1525–31.
Friedman R. J. Optimal duration of prophylaxis for venous thromboembolism following total hip arthroplasty and total knee arthroplasty [Text] / R. J. Friedman // J Am Acad Orthop Surg. — 2007. — V. 15. — P. 148–155.
A once-daily, oral, direct factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement [Text] / B. I. Eriksson, L. C. Borris, O. E. Dahl et al. // Circulation. — 2006. — V. 114. — P. 2374–2381.
Oral, direct factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement [Text] / B. I. Eriksson, L. Borris, O. E. Dahl et al. // J. Thromb Haemost. — 2006. — V. 4. — P. 121–128.
Dose-escalation study of rivaroxaban (BAY 59-7939) — an oral, direct factor Xa inhibitor — for the prevention of venous thromboembolism in patients undergoing total hip replacement [Text] / B. I. Eriksson, L. C. Borris, O. E. Dahl et al. // Thromb Res. — 2007. — V. 120. — P. 685–693.
Rabinov K. Roentgen diagnosis of venous thrombosis in the leg [Text] / K. Rabinov, S. Paulin // Arch Surg. — 1972. — V. 104. — P. 134–144.
Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement [Text] / D. Bergqvist, G. Benoni, O. Bjorgell et al. // N Engl J Med. — 1996. — V. 335. — P. 696–700.
Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty — the Danish Prolonged Prophylaxis (DaPP) Study [Text] / M. R. Lassen, L. C. Borris, B. S. Anderson et al. // Thromb Res. — 1998. — V. 89. — P. 281–287.
Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group [Text] / P. C. Comp, T. E. Spiro, R.J. Friedman et al. // J. Bone Joint Surg Am. — 2001. — V. 83-A. — P. 336–345.
Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study [Text] / P. Prandoni, O. Bruchi, P. Sabbion et al. // Arch Intern Med. — 2002. — V. 162. — P. 1966–1971.
Prolonged thromboprophylaxis following hip replacement surgery — results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin) [Text] / O. E. Dahl, G. Andreassen, T. Aspelin et al. // Thromb Haemost. — 1997. — V. 77. — P. 26–31.
Low-molecular-weight heparin prophylaxis using extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind randomized comparison. North American Fragmin Trial Investigators [Text] / R. D. Hull, G. F. Pineo, C. Francis et al. // Arch Intern Med. — 2000. — V. 160. — P. 2208–2215.
Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo [Text] / A. Planes, N. Vochelle, J. Y. Darmon et al. // Lancet. — 1996. — V. 348. — P. 224–228.
Oral rivaroxaban compared with subcutaneous enoxaparin for extended thromboprophylaxis after total hip arthroplasty: the RECORD1 trial [Text] / B. I. Eriksson, L. C. Borris, R. J. Friedman et al. // Blood. — 2007. — V. 110: abstract 6.
Rivaroxaban — an oral, direct factor Xa inhibitor — for thromboprophylaxis after total knee arthroplasty: the RECORD3 trial [Text] / M. R. Lassen, A.G. G. Turpie, N. Rosencher et al. // Blood. — 2007. — V. 110: abstract 308.
Orthopedic Surgery Transfusion Hemoglobin European Overview (OSTHEO) study: blood management in elective knee and hip arthroplasty in Europe [Text] / N. Rosencher, H. E. Kerkkamp, G. Macheras et al. // Transfusion. — 2003. — V. 43. — P. 459–469.
Dahl O. E. Orthopaedic surgery as a model for drug development in thrombosis [Text] / O. E. Dahl // Drugs. — 2004. — V. 64 (suppl 1). — P. 17–25.
Kakkar A. K. Compliance with recommended prophylaxis for venous thromboembolism: improving the use and rate of uptake of clinical practice guidelines [Text] / A. K. Kakkar, B. L. Davidson, S. K. Haas // J. Thromb Haemost. — 2004. — V. 2. — P. 221–227.
Copyright (c) 2014 Oleg Vyrva
This work is licensed under a Creative Commons Attribution 4.0 International License.
The authors retain the right of authorship of their manuscript and pass the journal the right of the first publication of this article, which automatically become available after 6 months from the date of publication under the terms of Creative Commons Attribution License, which allows others to freely distribute the published manuscript with mandatory linking to authors of the original research and the first publication of this one in this journal.
Authors have the right to enter into a separate supplemental agreement on the additional non-exclusive distribution of manuscript in the form in which it was published by the journal (i.e. to put work in electronic storage of an institution or publish as a part of the book) while maintaining the reference to the first publication of the manuscript in this journal.
The editorial policy of the journal allows authors and encourages manuscript accommodation online (i.e. in storage of an institution or on the personal websites) as before submission of the manuscript to the editorial office, and during its editorial processing because it contributes to productive scientific discussion and positively affects the efficiency and dynamics of the published manuscript citation (see The Effect of Open Access).